Cue生物制药 CUE 深 沪
交易中 03-30 11:40:22 美东时间
0.2271
-0.012
-5.14%
华盛通- 最 高0.2336
- 今 开0.225
- 成交量 18.02万股
- 最 低 0.2199
- 昨 收 0.2394
- 总市值 2072.01万
- 52周最高 1.03
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 0.2199
- 委 比 -27.91%
- 总股本 9123.77万
- 历史最高 31.69
- 量 比 0.69
- 振 幅 5.72%
- 历史最低 0.2199
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cue Biopharma Names Lucinda Warren Interim Chief Executive
The latest announcement is out from Cue Biopharma ( ($CUE) ). On March 26, 2026...
03-28 04:49
Cue Biopharma President, CEO Usman Azam Steps Down, Effective March 26; Lucinda Warren Named Interim President, CEO
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of
03-28 04:06
Cue Biopharma Announces CEO Transition
Lucinda Warren, a seasoned industry veteran, has been appointed as the interim President and CEO of Cue Biopharma, replacing Usman Azam who stepped down. The company, focused on developing innovative biologics to target disease-specific T cells for autoimmune and inflammatory diseases, is advancing its lead asset CUE-401 toward clinical trials. Warren brings over 30 years of experience in business development and leadership, having executed key d...
03-27 20:05
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
Cue Biopharma to Host Virtual R&D Day on April 7, 2026, featuring KOLs Richard DiPaolo, PhD, and Jonathan Kay, MD, discussing CUE-401, a novel biologic targeting autoimmune and inflammatory diseases by regulating proinflammatory mechanisms and inducing regulatory T cell differentiation. The event will include live Q&A and webcast available on Cue Biopharma's website for 30 days.
03-26 12:00
Cue Biopharma Files Prospectus For Up To $300M Offering Of Debt, Stock, Warrants, And Units
Debt SecuritiesCommon StockPreferred StockSubscription RightsUnitsWarrantsWe may offer and sell securities from time to time in one or more offerings of up to $300,000,000 in aggregate offering price. This prospectus
03-17 23:34
Cue Biopharma shares are trading higher after the company reported better-than-expected Q4 EPS results and a year-over-year increase in Q4 sales results.
Cue Biopharma shares are trading higher after the company reported better-than-...
03-17 04:25
Cue Biopharma Q4 EPS $0.01 Beats $(0.10) Estimate, Sales $21.942M Up From $1.576M Prior Year
Cue Biopharma (NASDAQ:CUE) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.10) by 110 percent. This is a 107.69 percent increase over losses of $(0.13) per share from the
03-17 04:19
Cue Biopharma To Deliver Poster Presentation On Lead Asset, CUE-401, At World Immune Regulation Meeting 2026
Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of
03-09 20:02
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
Boston, March 9, 2026 – Cue Biopharma, Inc. (Nasdaq: CUE) announced it will present new in vitro data on its lead asset, CUE-401, at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland on March 12, 2026. CUE-401 is a novel bifunctional TGF-beta/IL-2 fusion protein designed to restore immune balance by directly inhibiting proinflammatory immune cells and promoting regulatory T cell responses. The presentation will highlight its potent...
03-09 12:00
